Truveta Showcases Real-World Data Capabilities Through Dexcom CGM-EHR Integration

Truveta has shared an update.

The company highlighted a collaboration in which Dexcom linked proprietary continuous glucose monitoring (CGM) device data with longitudinal electronic health record (EHR) data for more than 200,000 patients using Truveta Live Link. The integrated dataset connects continuous glucose readings with diagnoses, medications, and clinical outcomes across patients’ care journeys. Early analyses cited in the post indicate that CGM use was associated with slower progression of chronic kidney disease and a 14% reduction in the rate of kidney function decline.

For investors, this update underscores Truveta’s role as a health data and analytics platform capable of linking large-scale proprietary device data with real-world clinical records. Demonstrated use cases like the Dexcom project can strengthen Truveta’s value proposition to medical device manufacturers, pharmaceutical companies, and other healthcare stakeholders engaged in R&D, clinical trials, and regulatory submissions. The ability to generate real-world evidence at scale may support future revenue growth through expanded partnerships and data-driven services. It also positions Truveta competitively in the real-world data and evidence generation market, where regulatory agencies and industry participants are increasingly seeking high-quality, linked datasets to support decision-making. While the post does not disclose financial terms or customer concentration, the case study suggests that Truveta’s platform is gaining traction in high-value applications that could support longer-term commercial adoption and recurring data analytics revenue.